IRD · Opus Genetics, Inc. · Metrics
Market Cap
$430.12M
Shares
83.20M
IRD metrics
61 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$5.18
Market cap
$430.12M
Price action
20 metricsPrice change (1W)
-14.2%
Price change (30D)
+27.9%
Price change (3M)
+27.3%
Price change (6M)
+18.0%
Price change (YTD)
+157.7%
Price change (1Y)
+247.7%
Trailing year
Price change (5Y)
-0.2%
52-week high
$6.07
52-week low
$1.49
Change from 52-week high
-14.7%
Change from 52-week low
+247.7%
Annualized volatility
82.3%
Annualized volatility (3M)
96.7%
Beta
1.2
RSI (14D)
58.1
Price vs SMA 50
+28.6%
Price vs SMA 200
+34.3%
Avg volume (3M)
2.28M
Relative volume
2.4
Average dollar volume
$11.24M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
83.20M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
43.6×
reciprocal yield 2.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-25.0%
Historical valuation
8 metricsP / E historical average (3Y)
4.1×
reciprocal yield 24.7%
P / E historical average (5Y)
4.1×
reciprocal yield 24.7%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2023-11-13
Profitability
9 metricsGross margin
—
Operating margin
-513.5%
Trailing 12 months
Net margin
-1,091.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$50.61M
Net income (TTM)
−$107.61M
Trailing 12 months
Diluted EPS (TTM)
$-1.33
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-73.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.86M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+75.8%
Year over year · more shares
Revenue CAGR (3Y)
-29.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-115.7%
Debt / equity
—
Current ratio
12.2
EBITDA (TTM)
−$894,662
Free cash flow (TTM)
—
Quick ratio
12.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$88.81M
Total assets
$92.97M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$40.67M
Capital expenditures (TTM)
—
R&D (TTM)
$38.62M
SG&A (TTM)
—
Stock compensation (TTM)
$4.46M
R&D / revenue
391.9%
Stock compensation / revenue
45.3%
Ownership (13F)
3 metrics13F filers
103
13F filer change QoQ
+24
Institutional ownership
69.2%
Short interest
3 metricsShort interest
13.1%
Latest settlement · 12.4 days to cover
Days to cover
12.4d
Short-squeeze score
79 / 100
Insider activity
2 metricsNet insider buying (90D)
−$213,798
Insider-sentiment score
28 / 100
Risk flags
1 metricsGoing concern
—